U.S. markets open in 1 hour 24 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.50+0.17 (+0.93%)
At close: 04:00PM EDT
18.50 0.00 (0.00%)
Pre-Market: 07:03AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close18.33
Bid15.00 x 4000
Ask21.00 x 1300
Day's Range17.83 - 19.18
52 Week Range10.41 - 21.29
Avg. Volume640,195
Market Cap1.233B
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-1.99
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for KURA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kura Oncology, Inc.
    Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Investor's Business Daily

    Kura Oncology Stock Scores Rising Relative Strength

    Kura Oncology had its Relative Strength (RS) Rating stock upgraded from 81 to 93 Thursday. Over 100 years of market history shows that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest price moves. Is Kura Oncology Stock A Buy?

  • GlobeNewswire

    Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

    WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. “As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team” said Jonathan Violin, Ph.D., Viridia

  • GlobeNewswire

    Celularity Appoints Industry Leader Diane Parks to its Board of Directors

    Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercializati